

CLAIMS

1. A cyotherapeutic unit comprising a plurality of potent cells; the content of said unit being known with respect to the identities and numbers at least some of said plurality; the unit being assayed to ensure the accuracy of said identities and numbers.
2. The cyotherapeutic unit of claim 1 wherein the accuracy of the assay is certified by the provider of the unit.
3. The cyotherapeutic unit of claim 1 wherein the potent cells for which the identities and numbers are known are pluripotent cells.
4. The cyotherapeutic unit of claim 1 wherein said identities reflect the presence or absence of at least one antigenic determinant on identified cells.
5. The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from fetal cord blood or other fetal tissue.
6. The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from fetal cord blood.
7. The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from placenta.
8. The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from postpartum placenta.
9. The cyotherapeutic unit of claim 1 wherein said potent cells are obtained from postpartum placenta perfusate.
10. The cyotherapeutic unit of claim 1 wherein potent cells for which the identities and numbers are known comprise at least some of cells exhibiting CD34, CD8, CD10, OCT4.
11. The cyotherapeutic unit of claim 1 wherein potent cells are derived from a plurality of sources.

12. The cytotherapeutic unit of claim 1 wherein potent cells are derived from at least two individuals.
13. The cytotherapeutic unit of claim 1 wherein potent cells are derived from at least 5 individuals
14. The cytotherapeutic unit of claim 1 wherein potent cells are genetically modified.
15. The cytotherapeutic unit of claim 1 wherein at least one type of cell is excluded from the unit.
16. The cytotherapeutic unit of claim 1 wherein the plurality of potent cells is selected to render the cytotherapeutic unit suitable for therapy for an indicated disease state or condition.
17. The cytotherapeutic unit of claim 16 wherein at least one type of cell is excluded from the unit.
18. A cytotherapeutic unit comprising minimum numbers of preselected types of potent cells.
19. The cytotherapeutic unit of claim 18 which has been assayed to ensure accuracy of its contents of preselected types of potent cells.
20. The cytotherapeutic unit of claim 18 wherein the contents of preselected potent cells is certified.
21. The cytotherapeutic unit of claim 18 wherein at least one type of cell is excluded from the unit.
22. The cytotherapeutic unit of claim 21 wherein the contents of preselected potent cells and the absence the types of cells to be excluded is certified.
23. The cytotherapeutic unit of Claim 18, wherein said certification is of a plurality of potent cell types, said plurality and the numbers of each of said plurality

being selected to render the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.

24. The cyotherapeutic unit of Claim 23, wherein said certification is of a plurality of potent cell types, said plurality and the numbers of each of said plurality being selected as well as the types of cells excluded renders the cyotherapeutic unit suitable for therapy for an indicated disease state or condition.

25. The cyotherapeutic unit of Claim 18 where at least some potent cells are genetically modified.

26. A kit for treatment of a person suspected of having a disease state or condition comprising a cyotherapeutic unit comprising a plurality of potent cells; the content of said unit being known with respect to the identities and numbers at least some of said plurality; the unit being assayed to ensure the accuracy of said identities and numbers; and a certification of the accuracy of the assay.

27. The kit of claim 26 wherein at least one type of cell has been excluded from the cyotherapeutic unit.

28. A kit for treatment of a person suspected of having a disease state or condition comprising a cyotherapeutic unit having minimum numbers of identified potent cells and a certification of the potent cell composition of the unit.

29. The kit of claim 28 wherein at least one type of cell has been excluded from the cyotherapeutic unit.

30. The kit of claim 28 wherein at least some cells are genetically modified.

31. A cyotherapeutic unit comprising cells derived from umbilical cord blood, placenta, or a mixture thereof, wherein at least one type of cell has been removed from the unit.

32. The cyotherapeutic unit of claim 31 wherein a plurality of cell types have been removed from the unit.
33. The cyotherapeutic unit of claim 31 wherein at least some cells of the unit are genetically modified.
34. A cyotherapeutic unit comprising cells derived from umbilical cord blood, placenta, or a mixture thereof, said cells comprising a plurality of different types, at least some of the different types having been separated into components and recombined into said unit.
35. The cyotherapeutic unit of claim 34, wherein said separated cell types have been frozen separately.
36. The cyotherapeutic unit of claim 34, in a frozen state.
37. The cyotherapeutic unit of claim 34, wherein said separated cell types have been characterized.
38. The cyotherapeutic unit of claim 34, wherein said separated cell types have been genetically modified
39. A method of treating a disease in a mammal comprising:
Administering to said mammal a therapeutically effective amount of a composition comprising: a cyotherapeutic unit comprising a plurality of potent cells; the content of said unit being known with respect to the identities and numbers of at least some of said plurality; the unit being assayed to ensure the accuracy of said identities and numbers.
40. The method of claim 39, wherein the cyotherapeutic unit comprises minimum numbers of preselected types of potent cells.
41. The method of claim 39, wherein the accuracy of said identities and numbers is certified.

42. The method of claim 39, wherein the cyotherapeutic unit is derived from post-partum placenta.
43. The method of claim 39, wherein the cyotherapeutic unit is derived from post-partum placenta perfusate.
44. The method of claim 39, wherein said unit comprises at least one cell that is autologous.
45. The method of claim 39, wherein said unit comprises at least one cell that is exogenous.
46. The method of claim 39, wherein said unit is administered multiple times.
47. The method of claim 39, wherein said method further comprises administering multiples of said units that are derived from different individuals.
48. The method of claim 39, wherein said method further comprises administering multiples of said units that are derived from different sources.
49. The method of claim 39, wherein said method further comprises administering multiple units that are genetically modified.
50. A library of cyotherapeutic units, each unit member of said library comprising a plurality of potent cells; the content of each of said units being known with respect to the identities and numbers at least some of the plurality of potent cells comprising said unit; each of said units being assayed to ensure the accuracy of said identities and numbers.
51. A method of treatment of a patient in need of cyotherapeutic treatment comprising selecting from a library of cyotherapeutic units at least two unit members of said library; combining aliquots from said unit members to form a treatment unit and administering said treatment unit to the patient.

52. The method of claim 51 wherein each of the unit members of the library has been assayed to determine the identity and numbers of potent cells present in said unit member.

53. The method of claim 51 wherein at least one of said unit members of the library has been reduced in at least one selected cell population.